NICE
NICE recommends RoActemra for early use in arthritis
October 13, 2011Sales and Marketing NICE, RoActemra
NICE has recommended Roche’s drug RoActemra be used at an earlier stage for some arthritis patients. In draft guidance NICE …
NICE says no to lupus treatment
September 30, 2011Sales and Marketing Benylsta, GSK, Lupus, NICE
NICE has rejected GSK’s new lupus treatment Benlysta in draft guidance.Co-developed with biotech company HGS, the drug has been hailed …
NICE refuses to back Sanofi’s Jevtana
September 30, 2011Sales and Marketing Jevtana, NICE
NICE has not recommended Sanofi’s prostate cancer drug Jevtana due to its high cost and concerns over its safety data. …
NICE blames pharma R&D model for spiralling cancer drug costs
September 29, 2011Research and Development, Sales and Marketing Cancer, NICE, clincial trials
NICE has blamed the pharma industry’s ‘inefficient’ and increasingly costly R&D model for the rising price of cancer drugs. NICE …
Merck’s COPD drug rejected by NICE
September 15, 2011Sales and Marketing Daxas, MSD, Merck & Co, NICE, roflumilast
NICE has not recommended Merck Co’s Daxas and has advised the firm to conduct a clinical trial in order to …
NICE recommends Takeda’s cancer drug Mepact
September 7, 2011Sales and Marketing Mepact, NICE, Takeda
NICE has reversed its stance on Mepact and recommended the bone cancer drug after re-examining discounts and a new patient …
NICE rejects three bowel cancer drugs
September 5, 2011Sales and Marketing Erbitux, NICE, Vectibix, avastin, colorectal cancer
NICE says three treatments – Roche’s Avastin, Merck KgAa’s Erbitux and Amgen’s Vectibix – are all not cost effective in …
MSD sways NICE with Simponi patient access scheme
August 26, 2011Sales and Marketing NICE, Simponi, ankylosing spondylitis
A patient access scheme which lowers Simponi’s cost has led to Merck Sharp and Dohme’s drug being given the thumbs …
NICE says no to BMS for second-line Orencia
August 25, 2011Sales and Marketing BMS, NICE, Orencia, rheumatoid arthritis
In final draft guidance NICE has not recommended the use of Bristol-Myers Squibb’s arthritis drug Orencia after other drugs have …
NICE blames Faslodex rejection on uncertainties in AZ data
August 23, 2011Sales and Marketing AstraZeneca, Faslodex, NICE, breast cancer
NICE has not recommended a high-dose form of AstraZeneca’s breast cancer drug Faslodex because of uncertainties over its cost-effectiveness. In …
New discount persuades NICE to back Novartis’ Tasigna
August 18, 2011Sales and Marketing Glivec, NICE, Sprycel, Tasigna
NICE has recommended Novartis’ Tasigna for use in the NHS after the blood cancer drug’s manufacturer submitted a new patient …
NICE to review Lucentis decision
August 17, 2011Sales and Marketing Lucentis, NICE, diabetic macular edema
NICE will allow an appeal against its decision not to recommend Novartis’s Lucentis for diabetic macular oedema. The appeal came …
NICE wants more information on Pradaxa
August 17, 2011Sales and Marketing NICE, Pradaxa
NICE has asked for more information on Pradaxa, after deciding in preliminary guidance that the drug is not cost-effective in …
NICE wants more RoActemra data for juvenile idiopathic arthritis
August 9, 2011Medical Communications NICE, RoActemra, Roche
NICE has requested more evidence from Roche for RoActemra in childhood arthritis. RoActemra (tocilizumab) is being assessed for the treatment …
Gilenya rejected by NICE
August 5, 2011Medical Communications, Sales and Marketing MS, NICE, Novartis, gilenya
NICE has not recommended Novartis’ multiple sclerosis drug Gilenya because of its cost and ‘uncertainties over its clinical effectiveness’. Gilenya …
